Hebei Aoxing Group Pharmaceutical Co., Ltd. announced the approval of tiridine, an anaesthetic and pain relief drug, to be listed on the New York Stock Exchange

Aoxing Pharmaceutical Co., Ltd announced the approval of new drugs to be listed on the New York Stock Exchange on June 9 local time Aoxing Pharmaceutical Co., Ltd held a press conference on the New York Stock Exchange Yuezhenjiang, chief executive of Hebei Aoxing Group Pharmaceutical Co., Ltd., announced that after 12 years of research and development, two specifications of tiridine, an anesthetic and pain reliever, have been approved for production by the State Food and Drug Administration of China At present, the per capita use of anesthetics and pain relievers in China is far lower than that in developed countries, and the market prospect of such drugs in China is promising The picture shows the scene of the conference The company chose to release news on NYSE, fully reflecting the importance of capital market This good news will produce qualitative changes to Aoxing pharmaceutical industry, and the company will enter a new historical development period About Hebei Aoxing Group Pharmaceutical Co., Ltd Hebei Aoxing Group Pharmaceutical Co., Ltd was founded in 1997 It is a high-tech pharmaceutical enterprise that develops and produces new specialty drugs It passed GMP certification in 2004, with a total investment of 380 million yuan It is a key project of the province Last year, the company became the first pharmaceutical enterprise in China to establish a drug R & D center with German leibotek company At present, there are three products to fill the national gap Hebei Aoxing Group Pharmaceutical Co., Ltd started listing on NASDAQ on February 14, 2006